Sanmartí Raimon, Ruiz-Esquide Virginia, Bastida Carla, Soy Dolor
Arthritis Unit, Rheumatology Service, Hospital Clinic of Barcelona, Barcelona, Catalonia, Spain.
Pharmacy Service, Hospital Clinic of Barcelona, Barcelona, Catalonia, Spain.
Immunotherapy. 2018 Mar 1;10(6):447-464. doi: 10.2217/imt-2017-0173. Epub 2018 Mar 2.
Rheumatoid arthritis (RA) is the most prevalent immune-mediated chronic rheumatic disease and is associated with joint destruction and disability. Therapeutic strategies, including biological disease-modifying antirheumatic drugs (bDMARDs) have improved the prognosis and quality of life of RA patients. Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6 receptor licensed in 2009 that has demonstrated clinical efficacy in various adult RA populations. RA management guidelines and recommendations consider TCZ as one of the bDMARDS indicated after methotrexate or other conventional synthetic DMARDs and/or TNF inhibitors failure in adult RA. Of particular interest is the demonstration of its effectiveness in monotherapy in comparison with other bDMARDs. Recent observational studies have shown good results for the safety profile of TCZ with no new alert signals.
类风湿性关节炎（RA）是最常见的免疫介导的慢性风湿性疾病，与关节破坏和残疾相关。包括生物改善病情抗风湿药物（bDMARDs）在内的治疗策略改善了RA患者的预后和生活质量。托珠单抗（TCZ）是一种于2009年获批的抗IL-6受体人源化单克隆抗体，已在各类成年RA人群中显示出临床疗效。RA管理指南和建议将TCZ视为在甲氨蝶呤或其他传统合成DMARDs和/或TNF抑制剂对成年RA治疗失败后适用的bDMARDs之一。特别值得关注的是，与其他bDMARDs相比，其单药治疗有效性得到了证实。最近的观察性研究表明，TCZ的安全性良好，没有新的警示信号。
